Voloridge Investment Management LLC Sells 20,471 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)

Voloridge Investment Management LLC lowered its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 6.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 294,548 shares of the company's stock after selling 20,471 shares during the quarter. Voloridge Investment Management LLC owned 0.88% of TransMedics Group worth $18,365,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of TMDX. Braidwell LP acquired a new position in TransMedics Group during the fourth quarter valued at approximately $57,493,000. Norges Bank acquired a new position in TransMedics Group during the fourth quarter valued at approximately $22,861,000. Dimensional Fund Advisors LP grew its holdings in TransMedics Group by 1,565.5% during the fourth quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock valued at $16,820,000 after purchasing an additional 253,624 shares during the period. Emerald Advisers LLC grew its holdings in TransMedics Group by 146.3% during the fourth quarter. Emerald Advisers LLC now owns 371,711 shares of the company's stock valued at $23,176,000 after purchasing an additional 220,804 shares during the period. Finally, FIL Ltd grew its holdings in TransMedics Group by 28.0% during the fourth quarter. FIL Ltd now owns 1,000,358 shares of the company's stock valued at $62,372,000 after purchasing an additional 218,961 shares during the period. Institutional investors and hedge funds own 99.67% of the company's stock.

TransMedics Group Stock Up 1.7%

TransMedics Group stock opened at $123.34 on Friday. The stock has a market capitalization of $4.17 billion, a PE ratio of 131.21 and a beta of 1.91. TransMedics Group, Inc. has a twelve month low of $55.00 and a twelve month high of $177.37. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42. The company has a 50 day moving average of $88.46 and a 200-day moving average of $77.00.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.29 by $0.41. The business had revenue of $143.54 million for the quarter, compared to analyst estimates of $123.39 million. TransMedics Group had a net margin of 8.14% and a return on equity of 18.74%. The firm's revenue for the quarter was up 48.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.35 earnings per share. On average, equities research analysts anticipate that TransMedics Group, Inc. will post 1 EPS for the current fiscal year.

Analysts Set New Price Targets

TMDX has been the subject of a number of analyst reports. Oppenheimer boosted their price objective on shares of TransMedics Group from $125.00 to $130.00 and gave the company an "outperform" rating in a report on Friday, May 9th. Needham & Company LLC reiterated a "hold" rating on shares of TransMedics Group in a report on Wednesday, April 23rd. Canaccord Genuity Group reiterated a "buy" rating and issued a $104.00 price target on shares of TransMedics Group in a report on Tuesday, March 11th. Finally, Piper Sandler reiterated an "overweight" rating and issued a $125.00 price target (up previously from $105.00) on shares of TransMedics Group in a report on Friday, May 9th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, TransMedics Group presently has an average rating of "Moderate Buy" and an average target price of $126.70.

Insider Transactions at TransMedics Group

In other news, Director Edward M. Basile sold 6,000 shares of the business's stock in a transaction on Friday, May 9th. The shares were sold at an average price of $115.63, for a total value of $693,780.00. Following the sale, the director now owns 732 shares of the company's stock, valued at $84,641.16. The trade was a 89.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. 7.00% of the stock is currently owned by insiders.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.